Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference Product Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

NCT03332303
View directory record Official record
Conditions
Vulvar and Vaginal Atrophy
Interventions
Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream
Drug
Lead sponsor
Prasco LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

NCT05796362
View directory record Official record
Conditions
Infectious Disease, Drug Effect, Clinical Infection
Interventions
Azithromycin Oleogel (Oral and Rectal)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

NCT03499873
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 20, 2026, 2:08 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

NCT03179605
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Madera, California • Santa Ana, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

NCT06933368
View directory record Official record
Conditions
Dental Plaque, Gingivitis
Interventions
Crest Cavity Protection Toothpaste, Experimental Mouthwash
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults

NCT00782548
View directory record Official record
Conditions
Healthy
Interventions
KADIAN (morphine sulfate sustained-release) capsules, Avinza (morphine sulfate sustained-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
19 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 20, 2026, 2:08 AM EDT
Not listed Phase 2 Interventional

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

NCT03339258
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Doxazosin Mesylate, Extended Release, Placebo
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 20, 2026, 2:08 AM EDT
Completed No phase listed Observational

The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome

NCT02112513
View directory record Official record
Conditions
Neonatal Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Tacrolimus in Healthy Volunteers

NCT04725682
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tacrolimus
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 59 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 2:08 AM EDT
Recruiting Phase 3 Interventional

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
SNP-ACTH (1-39) Gel, Rituximab
Drug
Lead sponsor
Cerium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873
View directory record Official record
Conditions
Obesity
Interventions
ERX1000, Placebo
Drug
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

NCT01682408
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension

NCT00853190
View directory record Official record
Conditions
Healthy
Interventions
Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

NCT03879837
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler, Placebo pressurized metered dose inhaler
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.

NCT03780244
View directory record Official record
Conditions
Nasolabial Folds
Interventions
Sculptra Aesthetic 8ml, Sculptra Aesthetic 5ml
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

NCT01260948
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

NCT01247272
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine Hydrochloride, PROZAC WEEKLY®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 20, 2026, 2:08 AM EDT